CareCloud, Inc.
NASDAQ:CCLDMedical - Healthcare Information Services
+$0.04 today
- Market cap
- $101.27M
- Beta
- 1.51
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.23
Volume 0.53M
Average 0.58M
CCLD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
CareCloud, Inc.NASDAQ: CCLD
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $2.42M rose 95.6% year over year, ahead of the +84.3% change in trailing-twelve-month research & development. Sequentially, it fell 5.0% from the prior quarter. Over 3 fiscal years it compounded at +13.2% a year.
Context
- Research & development amounted to 5.3% of revenue in FY2025, up 1.9 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +95.6% holds above the trailing-twelve-month pace of +84.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 6.38M USD
- Year-over-year change
- +68.8%
- 4-year CAGR
- +9.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.38M | +68.8% |
| FY2024 | 2024-12-31 | 3.78M | -20.2% |
| FY2023 | 2023-12-31 | 4.74M | +7.6% |
| FY2022 | 2022-12-31 | 4.4M | -0.2% |
| FY2021 | 2021-12-31 | 4.41M | — |
Research & Development vs competitors
How CCLD compares with its peers on the latest reported figures
- CCLD's LTM Mar 2026 research & development of $7.56M is the 6th highest of the 10 companies compared; the peer median is $13.34M.
- Its year-over-year change of +84.3% is the highest of 8, against a peer median of -7.8%.
- Research & development amounts to 6.1% of revenue for CCLD, versus a peer median of 38.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $41.33M | -11.2% | -6.2% | 274.8% | |
| LTM Mar 2026 | $38.53M | -58.1% | — | 31.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $33.44M | +11.2% | +29.0% | 279.0% |
| LTM Mar 2026 | $21.18M | +82.5% | +30.2% | — | |
| LTM Mar 2026 | $13.34M | -7.2% | +1.9% | 38.8% | |
| LTM Mar 2026 | $7.56M | +84.3% | +13.2% | 6.1% | |
| LTM Mar 2026 | $5.46M | -7.8% | +691.2% | 106.3% | |
| LTM Mar 2026 | $3.33M | -25.7% | -9.5% | 6.0% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $365.75K | — | — | — |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CCLD) | $13.34M | -7.8% | +15.4% | 38.8% | |
Competitors are the stored peer set for CCLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 139.6M | 138.83M | 117.06M | 110.84M | 120.5M |
| Cost of Revenue | 86.92M | 84.43M | 70.82M | 60.84M | 64.46M |
| Gross Profit | 52.68M | 54.39M | 46.24M | 50M | 56.04M |
| Gross Margin | 37.7% | 39.2% | 39.5% | 45.1% | 46.5% |
| Research & Development | 4.41M | 4.4M | 4.74M | 3.78M | 6.38M |
| Selling, General & Admin | 33.06M | 33.61M | 31.11M | 22.36M | 23.2M |
| Operating Expenses | 49.15M | 47.78M | 93.36M | 40.87M | 44.55M |
| Depreciation & Amortization | 16.25M | 15.01M | 16.55M | 16.14M | 16.98M |
| EBITDA | 19.7M | 21.03M | (31.29M) | 25.05M | 28.26M |
| EBITDA Margin | 14.1% | 15.1% | -26.7% | 22.6% | 23.5% |
| Operating Income | 3.53M | 6.61M | (47.12M) | 9.12M | 11.5M |
| Operating Margin | 2.5% | 4.8% | -40.2% | 8.2% | 9.5% |
| Interest Income | 15K | 41K | 154K | 88K | 206K |
| Interest Expense | 455K | 405K | 1.19M | 900K | 287K |
| Other Income / Expenses | (536K) | (1M) | (1.92M) | (1.11M) | (500K) |
| Income Before Tax | 2.99M | 5.61M | (49.04M) | 8.01M | 11M |
| Pre-Tax Margin | 2.1% | 4.0% | -41.9% | 7.2% | 9.1% |
| Income Tax Expense | 157K | 177K | (364K) | 160K | 199K |
| Net Income | 2.84M | 5.43M | (48.67M) | 7.85M | 10.8M |
| Net Margin | 2.0% | 3.9% | -41.6% | 7.1% | 9.0% |
| EPS (Basic) | (0.77) | (0.67) | (4.11) | (0.28) | 0.10 |
| EPS (Diluted) | (0.77) | (0.67) | (4.11) | (0.28) | 0.10 |
| Weighted Avg Shares | 14.54M | 15.11M | 15.67M | 16.15M | 377.92M |
| Weighted Avg Shares (Diluted) | 14.54M | 15.11M | 15.67M | 16.15M | 379.54M |
CareCloud, Inc.
NASDAQ:CCLD
Intrinsic Alpha fair value
Locked
Current Price
$2.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.